Ocumetics Technology Corp · TSXV:OTC
Ocumetics Technology — Investor Presentation (September 2023)
36 slides from Ocumetics Technology's investor presentation, September 2023

Slide 1: Always In Focus
Always In Focus Ocumetics Technology Corp. Investor Presentation 2023

Slide 2: Disclaimer
DISCLAIMER Nothing contained in this presentation is or shall be relied upon as a promise, guarantee, representation of or warranty specific or implied as to future performance of Ocumetics Technology Corp. The forward-looking statements contained in this presentation are expressly qualified in thei

Slide 3: Company Highlights
COMPANY HIGHLIGHTS BACKGROUND OCUMETICS LENS • A Canadian research and product development company • An accommodating intraocular lens (IOL). that specializes in adaptive intraocular lens designs. • Natural lens is replaced with the Ocumetics Lens. • 14 years of research to develop the Ocumetics Len

Slide 4: The human eye is a marvel of nature.
The human eye is a marvel of nature.

Slide 5: How the Eye Works
HOW THE EYE WORKS HOW LIGHT ENTERS THE EYE ACCOMMODATION REFRACTIVE ERRORS CATARACTS Myopia Hyperopia LEARN MORE LEARN MORE LEARN MORE LEARN MORE LEARN MORE Light rays enter the eye through the Accommodation is the ability of the eye Refractive error means that the shape of A cataract is when your e

Slide 6: Current vision correction treatments have limitations.
Current vision correction treatments have limitations.

Slide 7: The Problem: Eyesight Deterioration
THE PROBLEM EYESIGHT DETERIORATION • The eye deteriorates as we age. The natural lens hardens, loses flexibility and can become cloudy. This leads to eye disorders including presbyopia and cataracts. • At any one time 2.2 billion people or 29% of the global population requires corrective lenses.2 •

Slide 8: LASIK and PRK Are Imperfect Treatments
LASIK AND PRK ARE IMPERFECT TREATMENTS LASIK EYE SURGERY PHOTOREFRACTIVE KERATECTOMY (PRK) Corneal flap is surgically cut Laser reshapes cornea Outer corneal layer removed Laser reshapes cornea open and folded back. depending on condition. completely. depending on condition. LASIK and PRK are imperf

Slide 9: Intraocular Lenses (IOLs)
INTRAOCULAR LENSES (IOLs) INTRAOCULAR LENSES (IOL) Removal of natural lens. Synthetic lens inserted into Current IOL options lens capsule. LEARN MORE include Monofocal and Multifocal IOLs. An Intraocular Lens is an artificial lens that replaces the focusing power of the natural lens that is surgical

Slide 10: Limitations with Intraocular Lenses (IOLs)
LIMITATIONS WITH INTRAOCULAR LENSES (IOLs) MONOFOCAL IOL MULTIFOCAL IOL Current Monofocal LEARN MORE LEARN MORE and Multifocal IOL Monofocal IOLs provide clear vision at Multifocal IOLs provide clear vision at options have numerous one distance. near and far distances. limitations. LIMITATIONS LIMIT

Slide 11: The Solution: Accommodating IOLs
THE SOLUTION: ACCOMMODATING IOLs ACCOMMODATING IOL Accommodating IOLs are the future of vision LEARN MORE correction surgery. Accommodating IOLs change shape like the eye’s natural lens, facilitating clear vision at various distances. ABOUT ACCOMMODATING IOLs • Accommodating IOLs can move or change

Slide 12: Imagine a world without the need for corrective lenses.
Imagine a world without the need for corrective lenses.

Slide 13: Introducing the Ocumetics Lens
INTRODUCING THE OCUMETICS LENS Ocumetics Technology Corp. Investor Presentation 2023 13

Slide 14: Ocumetics Lens
OCUMETICS LENS An accommodating IOL that replicates natural CLEAR VISION AT FREEDOM FROM GLASSES FACILITATES FUTURE ALL DISTANCES AND CONTACTS ENHANCEMENTS lens functionality and restores clear vision. Experience the design benefits of clear vision at any distance. Our advanced lens technology Imagi

Slide 15: How It Works
HOW IT WORKS HOW IT WORKS DESIGN SPECIFICATIONS • The Ocumetics Lens suspension system consists of cushions • A unique design element of the Ocumetics Lens proprietary that are designed to self-customize and conform to the suspension system is the ease for near point focus and unique parameters of e

Slide 16: Components
COMPONENTS CILIARY CONNECTION Uses natural kinetics of the eye’s ciliary GLARE ABSORPTION muscles and zonules to adjust lens. The lens retainer is specially designed to minimize glare and halos. LENS RETAINER SUSPENSION SYSTEM A docking station for the lens that LENS CAPSULE facilitates future lens

Slide 17: Procedure
PROCEDURE OCUMETICS LENS PROCEDURE Removal of natural lens. Ocumetics lens inserted into Retainer inserted into the lens Ocumetics lens and retainer lens capsule. capsule. resting in the lens capsule. LEARN MORE SUITABLE FOR ALL 30 MINUTES MINIMALLY INVASIVE PRESCRIPTIONS The Ocumetics Lens procedur

Slide 18: Market Applications
MARKET APPLICATIONS 1 2 3 The Ocumetics lens has immediate market CATARACT GENERAL VISION FUTURE EMPHASIS CORRECTION DEVELOPMENTS relevancy and immense future potential. The initial focus for the Ocumetics Lens is to become the lens of choice for cataract lens Once established in the market, the Ocu

Slide 19: Our vision is to enhance lives, globally.
Our vision is to enhance lives, globally.

Slide 20: Target Market
TARGET MARKET TARGET MARKET MARKET GROWTH DRIVERS • Accommodating intraocular lens market segment. • Aging population and rising income levels. The market for • Individuals over 45 requiring lens replacement due to cataracts. • Increasing number of cataract surgeries. • Middle class or above. • Incr

Slide 21: Global Market Size
GLOBAL MARKET SIZE $158 BILLION Global eyewear market (2021) in USD. 13 24 MILLION Annual global cataract surgeries (2020). 14 The Ocumetics Lens has global market $6.4 BILLION potential. Projected intraocular lens segment by 2030 in USD. 15 4.9% Intraocular lens segment projected cumulative annual

Slide 22: Business Model
BUSINESS MODEL MANUFACTURING DISTRIBUTION RETAIL (CLINIC) Low cost mass Global sales Lens sales and procedure production. initiative. licensing. Outsourced production Production Direct Indirect Lens Procedure facility sales sales Ocumetics will outsource Direct sales to ophthalmologists Sales manage

Slide 23: Ocumetics aims to become a leader in the accommodating IOL segment.
Ocumetics aims to become a leader in the accommodating IOL segment.

Slide 24: The Competition
THE COMPETITION ATIA17 LUMINA18 The absence of • Modular, dual-optic presbyopia correcting IOL. • Modular, two-piece IOL. • Shape-changing, fluid filled based with fixed-power commercially available • Hydrophilic acrylic material. anterior optic for target refraction. • Sulcus-fixated haptics. • Res

Slide 25: Strong partnerships for a strong business.
Strong partnerships for a strong business.

Slide 26: Partners
PARTNERS Tooling design and manufacturer Bioana Prototype lens design and manufacturer CRC Clinical Research Consultants Inc. Regulatory advisors Ocular Technology Inc. Prototype lens design and manufacture NuSil Avantar Supplier of the silicon in fabricating the Ocumetics Lens The University of Uta

Slide 27: Patents & Regulatory
PATENTS & REGULATORY REGISTRATIONS • Filed with The World International Patent Office (WIPO). • Application for the Inflatable Lens/Lens Retainer registered on Aug 13, 2007. • Two supplemental submissions registered on Nov 5, 2007 and May 7, 2008. • Patent applications were examined for Novelty, Inv

Slide 28: A clear path to success.
ocumetics A clear path to success.

Slide 29: Roadmap
ROADMAP • Begin multi-center pivotal clinical trial Phase 1 • Completion of first-in-human (FIH) clinical trial (Dominican Republic) • FDA IDE annual report and interim analysis • CE Mark/HC license submission 2024 2026 2023 2025 2027 • Begin first-in-human (FIH) clinical trial (Dominican Republic)

Slide 30: Leadership on all fronts.
Leadership on all fronts.

Slide 31: Management Team
MANAGEMENT TEAM DEAN E. BURNS BSc DR. GARTH WEBB PRESIDENT, CEO & DIRECTOR FOUNDER, CSO & DIRECTOR • Business executive, scientist and medical device brand marketing • Founder of Ocumetics with a mission to empower people to see expert with over 38 years of healthcare experience, including 27 and be

Slide 32: Management Team
MANAGEMENT TEAM DR. DOYLE STULTING ROGER JEWETT CA, CPA CMO & DIRECTOR CFO & DIRECTOR • Director of the Stulting Research Center, Woolfson Eye Institute, • Hands-on executive with 25+ years of experience leading public and Atlanta, GA. private companies through corporate restructurings, financings a

Slide 33: Board of Directors
BOARD OF DIRECTORS DR. JAMES BARTON MCROBERTS O.D. DAYTON MARKS ROBERT QUINN DIRECTOR DIRECTOR DIRECTOR • Received Doctorate in Optometry from the University of Waterloo • Director, Bonanza Mining Corporation. • Independent businessman with years of diverse in 1974. • Sessional Instructional Assista

Slide 34: Investment Details
INVESTMENT DETAILS CAP TABLE (SEPT 2023) USE OF FUNDS COMMON SHARES OUTSTANDING 118,466,104 OPTIONS 10,157,117 Company Working Overhead Capital WARRANTS 2,413,454 TOTAL SHARES, FULLY DILUTED 131,036,675 Commence Clinical Trials NOTES • Completed RTO transaction in Q3 2021 • Raised $2.7M in Q3 2021 •

Slide 35: Contact Us
CONTACT US DEAN E. BURNS PRESIDENT, CEO & DIRECTOR (817) 874-7564 deantx69@gmail.com DAYTON MARKS DIRECTOR Learn more at (778) 347-2500 ocumetics.com dayton.marks@ocumetics.com is listed on the TSX:V, Frankfurt Stock Exchange and OTCQB Ocumetics Technology Corp. Investor Presentation 2023 35

Slide 36: References
REFERENCES 1. National Eye Institute. (2023). Cataracts. nei.nih.gov 2. World Health Organization. (2021). Blindness and vision impairment. who.int 3. Holden, B. A., Fricke, T. R., Wilson, D. A., Jong, M., Naidoo, K. S., Sankaridurg, P., ... & Resnikoff, S. (2016). Global prevalence of myopia and hi
Source: Internet Archive copy of ocumetics.com
More decks from Ocumetics Technology Corp
Investor Presentation (November 2026)37 slides · November 2026
Investor Presentation (March 2026)37 slides · March 2026
Investor Presentation (March 2026)22 slides · March 2026
Investor Presentation (November 2025)36 slides · November 2025
Investor Presentation (November 2025)19 slides · November 2025
Investor Presentation (June 2025)36 slides · June 2025